# A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

> **NCT04670679** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Erasca, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** ERAS-601
- **DRUG:** Cetuximab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04670679
- **Lead sponsor:** Erasca, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-15
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-06
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04670679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04670679, "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04670679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*